What's new? Log in Free sign up

IGM Biosciences (IGMS)

Company Profile

Company profile

Ticker

IGMS

Exchange

Website

CEO

Ms. Mary Beth Harler M.D.

Incorporated

Location

Fiscal year end

Sector

Health Technology > Biotechnology

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Alabama Power • Mississippi Power • Teva Pharmaceutical Industries Limited • Entergy Arkansas • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb ...

Former names

[object Object]

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

IGM Infectious Diseases, Inc. • IGM Autoimmunity and Inflammation, Inc. ...

IRS number

770349194

IGMS stock data

1M 3M 6M 1Y

Analyst ratings and price targets

Last 3 months

Average target

$23.50

Low target

$20.00

High target

$27.00

Latest filings (excl ownership)

View all

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

Cost Associated with Exit or Disposal Activities

Quarterly report

8 Nov 24

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

Issuer tender offer statement (amended)

Regulation FD Disclosure

Issuer tender offer statement (amended)

Issuer tender offer statement (amended)

Issuer tender offer statement

Information about tender offer

Transcripts

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Lisa Lynn Decker

Mary Beth Harler

Notice of proposed sale of securities

Notice of proposed sale of securities

PRICE T ROWE ASSOCIATES INC /MD/

Financial summary

Financial statements Chart IGMS financial data

Quarter (USD)	Sep 24	Dec 23	Sep 23	Jun 23
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 23	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	43.07 mm	43.07 mm	43.07 mm	43.07 mm	43.07 mm	43.07 mm
Cash burn (monthly)	23.35 mm	8.15 mm	21.46 mm	22.04 mm	(no burn)	10.60 mm
Cash used (since last report)	65.37 mm	22.81 mm	60.08 mm	61.70 mm	n/a	29.69 mm
Cash remaining	-22.30 mm	20.26 mm	-17.02 mm	-18.64 mm	n/a	13.38 mm
Runway (months of cash)	-1.0	2.5	-0.8	-0.8	n/a	1.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q2 2024

IGMS institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	85	76	+11.8%
Opened positions	24	68	-64.7%
Closed positions	15	1	+1400.0%
Increased positions	35	3	+1066.7%
Reduced positions	13	1	+1200.0%

13F shares	Current	Prev Q	Change
Total value	124.09 bn	100.31 bn	+23.7%
Total shares	33.99 mm	30.24 mm	+12.4%
Total puts	16.50 k	0.00	NEW
Total calls	39.50 k	1.10 k	+3490.9%
Total put/call ratio	0.4	–	–

Largest owners	Shares	Value	Change
Haldor Topsoe Holding A/S	10.40 mm	$93.81 mm	0.0%
Baker Bros. Advisors	4.09 mm	$28.10 bn	-1.3%
T. Rowe Price	4.08 mm	$28.00 mm	+4.8%
Artal	3.33 mm	$22.88 bn	+8.1%
Redmile	3.07 mm	$21.11 bn	NEW
GS The Goldman Sachs Group, Inc.	1.33 mm	$9.16 bn	+4.3%
Artal International S.C.A.	1.33 mm	$93.44 mm	0.0%
BLK BlackRock	883.08 k	$6.07 bn	+16.5%
Vanguard	878.62 k	$6.04 bn	+2.9%
FMR	818.87 k	$5.63 bn	-37.8%

Largest transactions	Shares	Bought/sold	Change
Redmile	3.07 mm	+3.07 mm	NEW
Ra Capital Management	0.00	-937.50 k	EXIT
FMR	818.87 k	-498.47 k	-37.8%
Millennium Management	391.21 k	+391.21 k	NEW
Artal	3.33 mm	+250.00 k	+8.1%
T. Rowe Price	4.08 mm	+187.07 k	+4.8%
Samsara BioCapital	154.66 k	+154.66 k	NEW
STT State Street	457.62 k	+138.35 k	+43.3%
Charles Schwab Investment Management	132.33 k	+132.33 k	NEW
D. E. Shaw & Co.	131.07 k	+131.07 k	NEW

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

IGMS insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
16 Dec 24	Mary Beth Harler	Common Stock	Sell	Dispose S	No	No	7.48	1,708	12.78 k	347,032
16 Dec 24	Misbah Tahir	Common Stock	Sell	Dispose S	No	No	7.48	1,708	12.78 k	187,653
16 Dec 24	Lisa Lynn Decker	Common Stock	Sell	Dispose S	No	No	7.48	1,063	7.95 k	78,041
16 Dec 24	Steven Weber	Common Stock	Sell	Dispose S	No	No	7.48	539	4.03 k	31,704
18 Nov 24	Misbah Tahir	Common Stock	Grant	Acquire A	No	No	0	66,667	0.00	189,361

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro

BMO Capital Initiates Coverage On IGM Biosciences with Outperform Rating, Announces Price Target of $21

BMO Capital analyst Etzer Darout initiates coverage on IGM Biosciences (NASDAQ:IGMS) with a Outperform rating and announces Price Target of $21.

Stifel Maintains Buy on IGM Biosciences, Raises Price Target to $27

Stifel analyst Stephen Willey maintains IGM Biosciences (NASDAQ:IGMS) with a Buy and raises the price target from $25 to $27.

IGM Biosciences Q3 2024 GAAP EPS $(1.01) Misses $(0.80) Estimate, Sales $516.000K Beat $267.222K Estimate

IGM Biosciences (NASDAQ:IGMS) reported quarterly losses of $(1.01) per share which missed the analyst consensus estimate of $(0.80) by 26.25 percent. The company reported quarterly sales of $516.000 thousand which beat

Quest Diagnostics Posts Upbeat Results, Joins GM, Philip Morris And Other Big Stocks Moving Higher On Tuesday

Crude Oil Up 2%; Siyata Mobile Shares Jump

Press releases

From Benzinga Pro

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

– Imvotamab (CD20 x CD3) trials in rheumatoid arthritis, systemic lupus erythematosus and myositis ongoing; initial clinical data expected by mid-2025 – – IGM-2644 (CD38 x CD3) expected to enter clinical study for

IGM Biosciences Announces Strategic Pivot to Focus Exclusively on Autoimmunity

– Company to prioritize its pipeline of T cell engagers in autoimmune diseases, including ongoing clinical development of imvotamab in rheumatoid arthritis and systemic lupus erythematosus – – Mary Beth Harler, M.D.,

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.